Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Acyclic Retinoid Combined With Tenascin-C-derived Peptide Reduces the Malignant Phenotype of Neuroblastoma Cells Through N-Myc Degradation

KAZUKI OTSUKA, MANABU SASADA, YU HIRANO, YUSUKE NOHARA, TAKUYA IYODA, YOSHIKAZU HIGAMI, HIROAKI KODAMA and FUMIO FUKAI
Anticancer Research July 2019, 39 (7) 3487-3492; DOI: https://doi.org/10.21873/anticanres.13494
KAZUKI OTSUKA
1Department of Molecular Patho-Physiology, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Japan
2Department of Molecular Pathology and Metabolic Disease, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MANABU SASADA
1Department of Molecular Patho-Physiology, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Japan
3Translational Research Center, Research Institutes for Science and Technology, Tokyo University of Science, Noda, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YU HIRANO
1Department of Molecular Patho-Physiology, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YUSUKE NOHARA
1Department of Molecular Patho-Physiology, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKUYA IYODA
4Department of Pharmacy, Faculty of Pharmaceutical Sciences, Sanyo-Onoda City University, Sanyo-Onoda, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YOSHIKAZU HIGAMI
2Department of Molecular Pathology and Metabolic Disease, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Japan
3Translational Research Center, Research Institutes for Science and Technology, Tokyo University of Science, Noda, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROAKI KODAMA
5Department of Biochemistry, Faculty of Science and Engineering, Saga University, Saga, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
FUMIO FUKAI
1Department of Molecular Patho-Physiology, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Japan
3Translational Research Center, Research Institutes for Science and Technology, Tokyo University of Science, Noda, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: fukai{at}rs.noda.tus.ac.jp
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 39 no. 7 3487-3492
DOI 
https://doi.org/10.21873/anticanres.13494
PMID 
31262872

Published By 
International Institute of Anticancer Research
Print ISSN 
0250-7005
Online ISSN 
1791-7530
History 
  • Received May 6, 2019
  • Revision received June 1, 2019
  • Accepted June 3, 2019
  • Published online July 1, 2019.

Copyright & Usage 
Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved

Author Information

  1. KAZUKI OTSUKA1,2,*,
  2. MANABU SASADA1,3,*,
  3. YU HIRANO1,
  4. YUSUKE NOHARA1,
  5. TAKUYA IYODA4,
  6. YOSHIKAZU HIGAMI2,3,
  7. HIROAKI KODAMA5 and
  8. FUMIO FUKAI1,3⇑
  1. 1Department of Molecular Patho-Physiology, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Japan
  2. 2Department of Molecular Pathology and Metabolic Disease, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Japan
  3. 3Translational Research Center, Research Institutes for Science and Technology, Tokyo University of Science, Noda, Japan
  4. 4Department of Pharmacy, Faculty of Pharmaceutical Sciences, Sanyo-Onoda City University, Sanyo-Onoda, Japan
  5. 5Department of Biochemistry, Faculty of Science and Engineering, Saga University, Saga, Japan
  1. Correspondence to: Fumio Fukai, Ph.D., Department of Molecular Patho-Physiology, Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan. Tel: +81 471241501 (Ext. 4645), Fax: +81 471213608, e-mail: fukai{at}rs.noda.tus.ac.jp
View Full Text

Statistics from Altmetric.com

Cited By...

  • 4 Citations
  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

PreviousNext
Back to top

In this issue

Anticancer Research
Vol. 39, Issue 7
July 2019
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Acyclic Retinoid Combined With Tenascin-C-derived Peptide Reduces the Malignant Phenotype of Neuroblastoma Cells Through N-Myc Degradation
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
6 + 1 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Acyclic Retinoid Combined With Tenascin-C-derived Peptide Reduces the Malignant Phenotype of Neuroblastoma Cells Through N-Myc Degradation
KAZUKI OTSUKA, MANABU SASADA, YU HIRANO, YUSUKE NOHARA, TAKUYA IYODA, YOSHIKAZU HIGAMI, HIROAKI KODAMA, FUMIO FUKAI
Anticancer Research Jul 2019, 39 (7) 3487-3492; DOI: 10.21873/anticanres.13494

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Acyclic Retinoid Combined With Tenascin-C-derived Peptide Reduces the Malignant Phenotype of Neuroblastoma Cells Through N-Myc Degradation
KAZUKI OTSUKA, MANABU SASADA, YU HIRANO, YUSUKE NOHARA, TAKUYA IYODA, YOSHIKAZU HIGAMI, HIROAKI KODAMA, FUMIO FUKAI
Anticancer Research Jul 2019, 39 (7) 3487-3492; DOI: 10.21873/anticanres.13494
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results and Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • Regulation and Function of CCL2 and N-Myc in Retinoic Acid-treated Neuroblastoma Cells
  • Google Scholar

More in this TOC Section

  • Fosnetupitant Versus Fosaprepitant for Delayed Vomiting Upon Irinotecan–Oxaliplatin Combination Chemotherapy for Pancreatic/Colorectal Cancer
  • MMP-9 Genotypes Serve as Oral Cancer Predictive Marker for Smokers
  • A RANKL-derived Peptide Inhibits RSPO3-LGR4-Wnt Signaling and Lung Adenocarcinoma in Mice
Show more Experimental Studies

Keywords

  • Neuroblastoma
  • proto-oncogene
  • MYCN
  • N-Myc
  • retinoic acid
  • all-trans retinoic acid
  • Acyclic retinoid
  • Tenascin-C
  • integrin
  • ubiquitin-proteasome system
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire